These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11206674)

  • 21. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol.
    Radauceanu A; Boivin JM; Bernaud C; Fay R; Zannad F;
    Fundam Clin Pharmacol; 2004 Aug; 18(4):483-91. PubMed ID: 15312156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy of carvedilol in severe hypertension.
    Ogihara T; Yoshinaga K; Kamahara Y; Ikeda M; Goto Y; Arakawa K; Iimura I; Ishii M; Kokubu T; Takeda T
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S69-72. PubMed ID: 1721983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapeutic efficacy of valsartan and valsartan/HCTZ in mild to moderate hypertensive patients].
    Sun NL; Wang HY; Zhu JR;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Aug; 35(8):715-8. PubMed ID: 17963629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
    Yarows SA; Oparil S; Patel S; Fang H; Zhang J
    Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study.
    Youn JC; Ihm SH; Bae JH; Park SM; Jeon DW; Jung BC; Park TH; Lee NH; Song JM; Yoon YW; Shin ES; Sung KC; Jung IH; Pyun WB; Joo SJ; Park WJ; Shin JH; Kang SM
    Clin Ther; 2014 Oct; 36(10):1412-21. PubMed ID: 25092393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension.
    Ruilope LM
    Am J Hypertens; 1994 Feb; 7(2):129-36. PubMed ID: 7910028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial.
    Calhoun DA; Lacourcière Y; Chiang YT; Glazer RD
    Hypertension; 2009 Jul; 54(1):32-9. PubMed ID: 19470877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
    White WB; Lacourciere Y; Davidai G
    Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.
    Solomon SD; Janardhanan R; Verma A; Bourgoun M; Daley WL; Purkayastha D; Lacourcière Y; Hippler SE; Fields H; Naqvi TZ; Mulvagh SL; Arnold JM; Thomas JD; Zile MR; Aurigemma GP;
    Lancet; 2007 Jun; 369(9579):2079-87. PubMed ID: 17586303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
    Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
    Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial.
    Erdoğan O; Ertem B; Altun A
    Anadolu Kardiyol Derg; 2011 Jun; 11(4):310-3. PubMed ID: 21543293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and non-insulin-dependent diabetes mellitus.
    Albergati F; Paternó E; Venuti RP; Boeri D; Lombardo I; Semino S; Viviani GL; Adezati L
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S86-9. PubMed ID: 1378156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy.
    Yoshida H; Akasaka H; Saitoh S; Shimamoto K; Miura T;
    Hypertens Res; 2014 Mar; 37(3):225-31. PubMed ID: 24108237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
    Smith DH; Dubiel R; Jones M
    Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
    Littlejohn T; Mroczek W; Marbury T; VanderMaelen CP; Dubiel RF
    Can J Cardiol; 2000 Sep; 16(9):1123-32. PubMed ID: 11021956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety of valsartan in obese and non-obese pediatric hypertensive patients.
    Meyers KE; Lieberman K; Solar-Yohay S; Han G; Shi V
    J Clin Hypertens (Greenwich); 2011 Oct; 13(10):758-66. PubMed ID: 21974764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age.
    Schaefer F; Coppo R; Bagga A; Senguttuvan P; Schlosshauer R; Zhang Y; Kadwa M
    J Hypertens; 2013 May; 31(5):993-1000. PubMed ID: 23511339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of carvedilol with atenolol in the treatment of mild-to-moderate essential hypertension. INT-CAR-07 (U.K.) Study Group.
    Young PH
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S82-5. PubMed ID: 1378155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.